Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study

David M Tuller, David R Bangsberg, Jude Senkungu, Norma C Ware, Nneka Emenyonu, Sheri D Weiser, David M Tuller, David R Bangsberg, Jude Senkungu, Norma C Ware, Nneka Emenyonu, Sheri D Weiser

Abstract

The cost of transportation for monthly clinic visits has been identified as a potential barrier to antiretroviral (ARV) adherence in sub-Saharan Africa and elsewhere, although there is limited data on this issue. We conducted open-ended interviews with 41 individuals living with HIV/AIDS and attending a clinic in Mbarara, Uganda, to understand structural barriers to ARV adherence and clinical care. Almost all respondents cited the need to locate funds for the monthly clinic visit as a constant source of stress and anxiety, and lack of money for transportation was a key factor in cases of missed doses and missed medical appointments. Participants struggled with competing demands between transport costs and other necessities such as food, housing and school fees. Our findings suggest that transportation costs can compromise both ARV adherence and access to care. Interventions that address this barrier will be important to ensure the success of ARV programs in sub-Saharan Africa.

References

    1. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (London, England) 2000;14(4):357–366.
    1. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (London, England) 2001;15(9):1181–1183.
    1. Bangsberg DR, Ware N, Simoni JM. Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS (London, England) 2006;20(1):140–141.
    1. Behforouz HL, Farmer PE, Mukherjee JS. From directly observed therapy to accompagnateurs: Enhancing AIDS treatment outcomes in Haiti and in Boston. Clinical Infectious Diseases. 2004;38(Supp 5):S429–S436. doi: 10.1086/421408.
    1. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. International Journal of STD and AIDS. 2005;16(1):38–41. doi: 10.1258/0956462052932548.
    1. Carlucci JG, Kamanga A, Sheneberger R, Shepherd BE, Jenkins CA, Spurrier J, Vermund SH. Predictors of adherence to antiretroviral therapy in rural Zambia. Journal of Acquired Immune Deficiency Syndromes. 2008;47(5):615–622. doi: 10.1097/QAI.0b013e318165dc25.
    1. Crane JT, Kawuma A, Oyugi JH, Byakika JT, Moss A, Bourgois P, Bangsberg DR. The price of adherence: Qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS and Behavior. 2006;10(4):437–442. doi: 10.1007/s10461-006-9080-z.
    1. Creswell J. Qualitative inquiry and research design: Choosing among five traditions. Thousand Oaks, CA: Sage Publications, Inc.; 1998.
    1. Farmer P. Pathologies of power: Rethinking health and human rights. American Journal of Public Health. 1999;89(10):1486–1496. doi: 10.2105/AJPH.89.10.1486.
    1. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS (London, England) 2005;19(12):1243–1249.
    1. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, Kglatwane J, Kinsman J, Kwasa R, Maridadi J, Moroka TM, Moyo S, Nakiyemba A, Nsimba S, Ogenyi R, Oyabba T, Temu F, Laing R. Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–665. doi: 10.1080/09540120701244943.
    1. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: A meta-analysis of the published literature. Clinical Infectious Diseases. 2005;41(2):217–224. doi: 10.1086/431199.
    1. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: The rural Haiti experience. AIDS (London, England) 2004;18(Suppl. 3):S21–S25.
    1. Kumarasamy N, Safren SA, Raminani SR, Pickard R, James R, Krishnan AK, Solomon S, Mayer KH. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: A qualitative study. AIDS Patient Care and STDs. 2005;19(8):526–537. doi: 10.1089/apc.2005.19.526.
    1. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, Faye MA, Gueye M, Laniece I, Toure Kane C, Liegeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E. The Senegalese government’s highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS (London, England) 2002;16(10):1363–1370.
    1. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, Wilson K, Buchan I, Gill CJ, Cooper C. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine. 2006;3(11):e438. doi: 10.1371/journal.pmed.0030438.
    1. Mshana GH, Wamoyi J, Busza J, Zaba B, Changalucha J, Kaluvya S, Urassa M. Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: A qualitative study of early rural referrals to the national program. AIDS Patient Care and STDs. 2006;20(9):649–657. doi: 10.1089/apc.2006.20.649.
    1. Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H. Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. Journal of Acquired Immune Deficiency Syndromes. 2006;43(Suppl. 1):S123–S126.
    1. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (London, England) 2003;17(9):1369–1375.
    1. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P, Bangsberg DR. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes. 2004;36(5):1100–1102. doi: 10.1097/00126334-200408150-00014.
    1. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: A systematic review. PLoS Medicine. 2007;4(10):e298. doi: 10.1371/journal.pmed.0040298.
    1. Safren SA, Kumarasamy N, James R, Raminani S, Solomon S, Mayer KH. ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care. 2005;17(7):853–862.
    1. Uganda Country Profile. (2008). United Kingdom Department for International Development. . Accessed 3 Oct 2008.
    1. Ware NC, Wyatt MA, Bangsberg DR. Examining theoretic models of adherence for validity in resource-limited settings. A heuristic approach. Journal of Acquired Immune Deficiency Syndromes. 2006;43(Suppl. 1):S18–S22.
    1. Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W, Mermin J, Buchacz K, Behumbiize P, Ransom RL, Bunnell R. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006;368(9547):1587–1594. doi: 10.1016/S0140-6736(06)69118-6.
    1. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, Kebaabetswe P, Dickenson D, Mompati K, Essex M, Marlink R. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes. 2003;34(3):281–288. doi: 10.1097/00126334-200311010-00004.
    1. Wood E, Hogg RS, Yip B, Quercia R, Harrigan PR, O’Shaughnessy MV, Montaner JS. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. The Journal of Infectious Diseases. 2003;188(10):1421–1425. doi: 10.1086/379201.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa